Interim data suggests reduced risk of progression or death in the CM24/nivolumab plus standard of care Nal-IRI/5FU/LV arm of the study The interim data in the CM24/nivolumab plus SoC Nal-IRI/5FU/LV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback